As anti-P2RX7 monoclonal antibodies (mAbs) have demonstrated efficacy in clinical trials for BCC [53], it is not unreasonable to attempt to engineer anti-P2RX4 monoclonal therapeutic antibodies with inhibitory abilities to block its downstream signaling pathways. Here, P2RX7 is linked to skin basal cell carcinoma.